2,2,2-Trifluoro-1-(4-hydroxyphenyl)ethanone, 95.0%, 1g

3(S)-3-Hydroxymethyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester, 98%, 500mg

(S)-2-((tert-Butoxycarbonyl)amino)-2-(4-(trifluoromethoxy)phenyl)acetic acid, 95%, 500mg

(2-Aminopyrimidin-4-yl)dimethylphosphine oxide, 98%, 1g

4-Bromoquinolin-3-amine, 97%, 5g

Sodium hydroxide solution, ROTIPURAN® min. 32%, pa, 1 l, plastic packaging.

1-(4-Bromo-1-ethyl-1H-pyrazol-3-yl)-ethanone, 250mg

5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one, 95.0%, 200mg

N-(tert-Butoxycarbonyl)-N'-methylethylenediamine>98.0%(T)5g

4'-(Hydroxymethyl)[1,1'-biphenyl]-3-carbaldehyde, 95.0%, 250mg

rac-(3R,4R)-4-amino-1-methyl-3-pyrrolidinol dihydrochloride, 95.0%, 5g

1-Chloro-6-fluoro-7-methoxyisoquinoline, 1g

Long working distance plan phase 4x/0.13 IOS objective, working distance 10.75 mm